



#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Peter A. Ward et al.

Serial No.:

09/651,685

08/30/00

Group No.:

1644

Filed:

Examiner:

A. Decloux

Entitled:

Compositions And Methods For The Treatment Of Sepsis

### AMENDMENT TRANSMITTAL

RECEIVED

Assistant Commissioner for Patents Washington, D.C. 20231

APR 2 9 2002

**TECH CENTER** 1600/2900

#### CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Assistant Commissioner for Patents, , P.O. Box 2327, Arlington, VA 22202.

Dated: (

Madam:

Transmitted herewith are:

- Substitute Sequence Listing (hard copy and on computer readable diskette); 1.
- 2. Certificate Re: Sequence Listing
- 3. Second Preliminary Amendment
- Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures.

No additional fee is required.

Please charge any additional fees, including any fees necessary for extensions of time, or credit overpayment to Deposit Account No. 08-1290. An originally executed duplicate of this transmittal is enclosed for this purpose.

Dated: 04/22/02

Thomas W. Brown

Registration No. 50,002

MEDLEN & CARROLL, LLP 101 Howard Street, Suite 350

San Francisco, California 94105

415.904.6500



COMMISSIONER FOR PATERS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20

## ATTACHMENT TO "NOTICE TO COMPLY WITH REQUIREMENTS...SEQUENCE DISCLOSURES"

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be submitted using one of the following methods:

- 1. Electronically submitted through EFS-Bio (<a href="http://www.uspto.gov/ebc/efs/downloads/documents.htm">http://www.uspto.gov/ebc/efs/downloads/documents.htm</a>, EFS Submission User Manual ePAVE)
- 2. Mailed to:

U.S. Patent and Trademark Office Box Sequence, P.O. Box 2327 Arlington, VA 22202

- Mailed by Federal Express, United Parcel Service or other delivery service to:
   U. S. Patent and Trademark Office
   2011 South Clark Place
   Customer Window, Box Sequence
   Crystal Plaza Two, Lobby, Room 1B03
   Arlington, Virginia 22202
- Hand Carried directly to the Customer Window at:
   2011 South Clark Place
   Crystal Plaza Two, Lobby, Room 1B03, Box Sequence,
   Arlington, Virginia 22202

Rev. 12/27/2001

# Application No.: 09/651,685 NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

	<ol> <li>This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.</li> </ol>
	2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
	3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
	4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
	6. The paper copy of the "Sequence Listing" is not the same as the computer readable from of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
X	7. Other: In Figures 8-9, 13-19, amino acid sequences or nucleic acid sequences are disclosed which have no SEQ ID NO: tag either in said figures or in the brief description of said figures.
Applicant Must Provide:	
X	An <u>initial</u> or substitute computer readable form (CRF) copy of the "Sequence Listing".
X	An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).
For	questions regarding compliance to these requirements, please contact:
For	r Rules Interpretation, call (703) 308-4216 r CRF Submission Help, call (703) 308-4212 tentIn Software Program Support (SIRA) Technical Assistance703-287-0200
	To Purchase Patentin Software703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE